Updated Jul 16, 2026
Gilliam Joseph E has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.53M.
Joseph E. Gilliam is the President and COO of Glaukos Corp, a company specializing in ophthalmic pharmaceuticals and medical technology. He has been involved in the company's operations and strategic direction, particularly in the commercialization of innovative therapies for eye diseases.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-29 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 1.1K | $142.57 | $151K |
| 2026-05-04 | GKOS | GLAUKOS Corp | S — Open-market sale | 19.6K | $143.54 | $2.81M |
| 2026-04-04 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 3.2K | $109.60 | $347K |
| 2026-03-28 | GKOS | GLAUKOS Corp | A — Grant or award | 17.8K | $0.00 | |
| 2026-03-28 | GKOS | GLAUKOS Corp | A — Grant or award | 5.8K | $0.00 | |
| 2026-03-26 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 7.4K | $105.23 | $777K |
| 2026-03-26 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 4.9K | $105.23 | $518K |
| 2026-03-26 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 2.8K | $106.84 | $300K |
| 2026-03-19 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 1.2K | $98.94 | $118K |
| 2026-03-18 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 2.5K | $97.02 | $239K |
| 2026-02-26 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 1.1K | $119.17 | $126K |
| 2026-01-27 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 3.2K | $129.28 | $413K |
| 2026-01-27 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 1.8K | $128.07 | $230K |
| 2026-01-27 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 3.1K | $127.03 | $394K |
| 2026-01-27 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 2.4K | $126.10 | $303K |
| 2026-01-27 | GKOS | GLAUKOS Corp | M — Option exercise [10b5-1] | 10.5K | $55.18 | $579K |
| 2026-01-24 | GKOS | GLAUKOS Corp | S — Open-market sale [10b5-1] | 4.5K | $124.65 | $561K |
| 2026-01-24 | GKOS | GLAUKOS Corp | M — Option exercise [10b5-1] | 4.5K | $55.18 | $248K |
| 2025-09-23 | GKOS | GLAUKOS Corp | F — Tax withholding / forfeiture | 1.1K | $84.69 | $89K |
| 2025-09-18 | GKOS | GLAUKOS Corp | A — Grant or award | 3.9K | $0.00 |
Joseph E. Gilliam is the President and COO of Glaukos Corp, a company specializing in ophthalmic pharmaceuticals and medical technology. He has been involved in the company's operations and strategic direction, particularly in the commercialization of innovative therapies for eye diseases.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 9 open-market sales ($5.53M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Gilliam Joseph E profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.